Justin Keywood
Justin Keywood is an analyst at Stifel who covers HLS Therapeutics Inc. He recently adjusted his target for the company while maintaining a hold rating, noting the challenges in meeting growth targets and the potential impact of share buybacks on stock performance amid limited liquidity.
Global Media Ratings
Countries Mentioned
No country-level mention data available.
Interactive World Map
Each country's color is based on "Mentions" from the table above.
Recent Mentions
Canada:
Stifel’s Justin Keywood bumped his Street-low HLS Therapeutics Inc. target to $4 with a 'hold' rating.
5